(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.
Metavia's earnings in 2026 is -$16,216,000.On average, 6 Wall Street analysts forecast MTVA's earnings for 2026 to be -$5,310,963, with the lowest MTVA earnings forecast at -$8,210,793, and the highest MTVA earnings forecast at -$1,132,591. On average, 6 Wall Street analysts forecast MTVA's earnings for 2027 to be -$4,692,825, with the lowest MTVA earnings forecast at -$7,831,061, and the highest MTVA earnings forecast at -$1,409,961.
In 2028, MTVA is forecast to generate -$10,283,799 in earnings, with the lowest earnings forecast at -$9,880,512 and the highest earnings forecast at -$10,586,263.